Investigate the effect of AZD1656 on the pharmacokinetics and pharmacodynamics of Warfarin in type 2 diabetes mellitus (T2DM) patients

Study identifier:D1020C00027

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-Label, Randomised, Placebo-Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated with Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Warfarin During Co-administration with AZD1656

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 1

Healthy volunteers

No

Study drug

Warfarin, Placebo, AZD1656

Sex

All

Actual Enrollment

16

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Apr 2010
Primary Completion Date: 01 Aug 2010
Study Completion Date: 01 Aug 2010

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria